Replimune REPL
NASDAQ REPL
$11.95 +0.53 (+4.64%)
As of: Oct 21, 2026 · 11:41 AM EDT

Replimune (REPL) EBITDA Margin (2017 - 2018)

Updated

Analysis

Replimune (REPL) EBITDA Margin (2017 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn 35.95%
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn 49.01%
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn -
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 33.11%
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn -124.26%
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn 39.16%
10 Replimune 1.15 Bn 96.66 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -1,145.12%
Sep 30, 2018 -1,064.46%
Jun 30, 2018 -2,575.33%
Dec 31, 2017 -14,690.63%
Sep 30, 2017 -42,290.00%
Jun 30, 2017 -10,510.00%
API Access

Replimune EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=REPL&period=max&api_key=YOUR_API_KEY